Device Trial Radar · NCT04241718
A Feasibility Study on Ultrafiltration and Blood Volume Measurements
Last checked: Nov 20, 2026Latest source record: Nov 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
6
Actual
Start
Dec 19, 2019
Primary completion
Dec 27, 2022
Study completion Dec 27, 2022
Sponsor
- Lead sponsor
- Nuwellis, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Daxor Corporation
- First posted
- Jan 27, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this feasibility study is to characterize the performance of the Aquadex FlexFlow® System with the hematocrit (HCT) feature in conjunction with Daxor's blood volume analyzer (BVA-100). The study will monitor blood volume changes during ultrafiltration (UF) therapy as a potential means to guide the removal of fluid in subjects hospitalized with acute decompensated heart failure (ADHF).
Conditions
- Acute Decompensated Heart Failure
- Fluid Overload
Interventions
Aquadex FlexFlow System and BVA-100Device
Aquapheresis therapy with Aquadex FlexFlow System and Blood Volume Measurement with BVA-100
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1. Evaluate changes in blood volume as measured by BVA from before initiation until completion of extracorporeal fluid removal by ultrafiltrationTime frame: Through study procedure completion, average of 2 weeks
- 2. Evaluate if changes in blood volume, as measured by BVA, correlate with changes in HCT as measured by the device embedded in the Aquadex FlexFlow System ultrafiltration deviceTime frame: Through study procedure completion, average of 2 weeks
- 3. Evaluate the temporal relationship between changes in blood volume, as measured by BVA , and changes in clinical signs and symptoms of fluid overloadTime frame: Through study procedure completion, average of 2 weeks
5 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Midwest Cardiovascular Institute
Naperville, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.